SCHEMBL2308342

SCHEMBL2308342

Cc1cc(Br)no1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL27810686 0.97
SCHEMBL13601928 0.71 KDM4E (0.41)
SCHEMBL5728 0.71
Ammonia Solution, Strong SCHEMBL7395872 0.69
SCHEMBL2124100 0.69
SCHEMBL24681579 0.69
SCHEMBL6607334 0.69
SCHEMBL15286864 0.67 RAB9A (0.42)
SCHEMBL4588205 0.67 RAB9A (0.50)
Hydrochloric Acid SCHEMBL10342317 0.67 MEN1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150291623-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2015-10-15 US claimed
US-20120295897-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2012-11-22 US claimed
EP-2350090-A2 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2011-08-03 EP claimed
US-20100137299-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2010-06-03 US claimed
WO-2010045251-A2 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS, INC. (CA) 2010-04-22 WO claimed
EP-1095043-A1 TRIOXANE DERIVATIVES The Hong Kong University of Science &amp; Technology (HK) 2001-05-02 EP claimed
WO-2000004026-A1 TRIOXANE DERIVATIVES THE HONG KONG UNIVERSITY OF SCIENCE & TECHNOLOGY (CN) 2000-01-27 WO claimed
EP-0974354-A1 Artemisinin derivatives The Hong Kong University of Science &amp; Technology (HK) 2000-01-26 EP claimed
CN-117586256-A Substituted heterocyclic compounds 首药控股(北京)股份有限公司 2024-02-23 CN disclosed
CN-114685341-A Spiro compounds used as indoleamine 2, 3-dioxygenase inhibitor 齐鲁制药有限公司 2022-07-01 CN disclosed
CN-114302886-A Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof 上海赛默罗生物科技有限公司 2022-04-08 CN disclosed
EP-3318557-A2 QUINOLONE COMPOUND Otsuka Pharmaceutical Co., Ltd. (JP) 2018-05-09 EP disclosed
US-9708323-B2 Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2017-07-18 US disclosed
US-20170137425-A1 TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL MYERS SQUIBB CO (US) 2017-05-18 US disclosed
WO-2000004026-A1 TRIOXANE DERIVATIVES THE HONG KONG UNIVERSITY OF SCIENCE & TECHNOLOGY (CN) 2000-01-27 WO disclosed
EP-0974354-A1 Artemisinin derivatives The Hong Kong University of Science &amp; Technology (HK) 2000-01-26 EP disclosed
EP-0207955-B1 PROCESS FOR THE PREPARATION OF 3,5-DISUBSTITUTED ISOXAZOLES ZAMBON S.p.A. (IT) 1990-02-07 EP disclosed
US-4772719-A FROM DIHALOFORMALDOXIME AND ALKYNE, CYCLIZATION ZAMBON S.P.A. (IT) 1988-09-20 US disclosed
EP-0207955-A1 PROCESS FOR THE PREPARATION OF 3,5-DISUBSTITUTED ISOXAZOLES. ZAMBON SPA (IT) 1987-01-14 EP disclosed
WO-1986003490-A1 PROCESS FOR THE PREPARATION OF 3,5-DISUBSTITUTED ISOXAZOLES ZAMBON S.P.A. (IT) 1986-06-19 WO disclosed